依库珠单抗(Eculizumab) - 药物靶点：C5_在研适应症：水通道蛋白4抗体阳性视神经脊髓炎谱系疾病，非典型溶血性尿毒症综合征，重症肌无力_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-C5 monoclonal antibody 5G1-1、Eculizumab (Genetical Recombination)、Eculizumab (genetical recombination) (JAN)

+ [16]

靶点

C5

作用方式

抑制剂

作用机制

C5抑制剂(补体C5抑制剂)

治疗领域

肿瘤免疫系统疾病感染+ [5]

在研适应症

水通道蛋白4抗体阳性视神经脊髓炎谱系疾病非典型溶血性尿毒症综合征重症肌无力+ [2]

非在研适应症

原研机构

Alexion Pharmaceuticals, Inc.

在研机构

Alexion Pharmaceuticals, Inc.Alexion Europe SAS

AstraZeneca Korea Co. Ltd.

+ [3]

非在研机构-

权益机构

Alexion Pharmaceuticals, Inc.

AstraZeneca PLC

最高研发阶段批准上市

首次获批日期

美国 (2007-03-16),

阵发性睡眠性血红蛋白尿症

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、孤儿药 (韩国)、孤儿药 (澳大利亚)、优先审评 (中国)

登录后查看时间轴

结构/序列

Sequence Code 66437L

来源: *****

Sequence Code 66453H

来源: *****

关联

73

项与依库珠单抗相关的临床试验

NCT05646563

/ Not yet recruiting临床2期

A Phase II, Open-Label Study of NM8074 in Soliris®-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 in PNH patients undergoing complement-inhibitor therapy with Soliris.

开始日期2027-01-01

申办/合作机构

NovelMed Therapeutics, Inc.

ChiCTR2600133029

/ SuspendedN/AIIT

Evaluation of eculizumab therapy in the acute-staged severe AQP-4 IgG antibody positive optic neuritis

开始日期2026-09-20

申办/合作机构

温州医科大学附属眼视光医院

NCT07010302

/ Recruiting临床4期IIT

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain. This trial compares the effectiveness and safety of five medications commonly used to prevent NMOSD relapses: rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab.
In this study, 160 adults with NMOSD who test positive for a specific antibody (AQP4-IgG) will participate. They will be randomly assigned to receive either rituximab or one of the four other FDA-approved medications. The main goal is to find out which treatment best prevents relapses and has fewer serious side effects. The trial will also measure disability, patient satisfaction, quality of life, and biomarkers that help track disease activity.
Participants will have regular assessments, including medical exams, surveys, and tests for vision, walking ability, and brain function. They will report any side effects or health issues experienced during the study. The trial will last from one to four years for each participant.
This research aims to help patients and doctors make better-informed treatment decisions by providing clear evidence about the best available therapies for NMOSD.

开始日期2026-09-01

申办/合作机构

The Massachusetts General Hospital

[+1]

100 项与依库珠单抗相关的临床结果

登录后查看更多信息

100 项与依库珠单抗相关的转化医学

登录后查看更多信息

100 项与依库珠单抗相关的专利（医药）

登录后查看更多信息

2,615

项与依库珠单抗相关的文献（医药）

2026-12-31·Hematology

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria

Article

作者: Onizuka, Makoto ; Ogawa, Yoshiaki ; Nasukawa, Miina ; Ogiya, Daisuke ; Koyama, Seina ; Machida, Shinichiro ; Shiraiwa, Sawako ; Kawada, Hiroshi ; Tomita, Shunsuke ; Endo, Motoki ; Toyosaki, Masako

OBJECTIVES:

Paroxysmal nocturnal hemoglobinuria (PNH) may develop breakthrough hemolysis (BTH) despite C5 inhibition. Although iptacopan, an oral factor B inhibitor, has demonstrated efficacy in phase 3 trials, switching from crovalimab has not been reported. We describe the first clinical case of this switch in a real-world clinical setting.

METHODS:

A 72-year-old man with long-standing PNH received eculizumab followed by crovalimab. Infectious enteritis triggered BTH and worsening anemia during crovalimab therapy. Because anemia persisted after recovery, iptacopan 200 mg twice daily was initiated three weeks after the final crovalimab administration. Clinical symptoms and laboratory parameters were followed for 12 months. This case report complied with the Declaration of Helsinki.

RESULTS:

Hemoglobin increased from 9.6 to 11.6 g/dL within two weeks and remained ≥12 g/dL thereafter. Dyspnea resolved within one week, vitality improved by two weeks, and no BTH or treatment-related adverse events occurred during follow-up.

DISCUSSION:

This case demonstrates the feasibility of switching from crovalimab to iptacopan despite the absence of an established method, and pharmacokinetic considerations guided the timing.

CONCLUSION:

Switching to iptacopan led to rapid and durable improvement in anemia and symptoms, supporting proximal complement inhibition as a valuable option for PNH patients inadequately controlled with C5 inhibitors.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making

Article

作者: Shafrin, Jason ; Muthukrishnan, Sanjana ; Kuypers, Nicholas ; Bilano, Ver ; Than, Kyi-Sin ; Paulose, Jincy

OBJECTIVE:

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and debilitating hematological disease with significant economic burden. Despite the availability of multiple therapies, there is a lack of consensus on optimal treatment strategies among physicians and payers in the United States. This study aimed to evaluate the economic value of iptacopan, a novel oral treatment option, compared to terminal complement inhibitors (specifically, complement component C5 inhibitor or C5i)-including eculizumab and ravulizumab-among patients with PNH who are either (i) C5i-experienced or (ii) complement-inhibitor-naïve.

METHODS:

A cost per responder analysis was conducted based on treatment efficacy from clinical trials comparing iptacopan with C5i treatments. Treatment response was defined as the proportion of patients achieving red blood cell transfusion independence. Treatment costs were estimated as pharmaceutical wholesale acquisition cost and treatment administration costs, accounting for discontinuation. Outcomes evaluated included the number needed to treat to achieve a response and the cost per responder over the treatment duration of 24 weeks.

RESULTS:

Over 24 weeks, the number needed to treat to achieve an additional response was lower for iptacopan than all C5i comparators (C5i-experienced: 1.05 with iptacopan vs. 3.86 with C5is; complement-inhibitor-naïve: 1.02 with iptacopan vs. 1.69 with C5is). Cost per responder was lower for iptacopan than C5i comparators for both C5i-experienced ($264,337 for iptacopan vs. $975,298 for ravulizumab, $1,060,511 for eculizumab, and $744,561-$955,194 for eculizumab biosimilar with 10%-30% discount from eculizumab cost) and complement-inhibitor-naïve patients ($256,754, vs. $428,139 for ravulizumab, $465,546 for eculizumab, and $326,849-$419,314 for eculizumab biosimilar).

CONCLUSION:

Among both C5i-experienced and complement-inhibitor-naïve patients, treatment with iptacopan resulted in higher response rates and lower cost per responder compared to C5is.

2026-12-01·JOURNAL OF THE NEUROLOGICAL SCIENCES

Meningococcal infection in patients receiving eculizumab or ravulizumab for generalized myasthenia gravis or neuromyelitis optica spectrum disorder: A real-world study of US clinical practice

Article

作者: Carrillo Infante, Cynthia ; Yang, Feifei ; Qureshi, Samirah ; Akpoji, Ukwen ; Gonsalves, Katie ; Koneru, Meghana ; Jha, Lokesh ; Pandya, Shirali

Eculizumab and ravulizumab are terminal complement inhibitors that are effective treatments approved for generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) among other indications. Treatment with terminal complement inhibitors is associated with increased risk of Neisseria meningitidis (Nm) infection. This study used post-marketing and pharmacovigilance data from the Alexion safety database to assess the cumulative exposure-adjusted Nm infection and mortality rates among US patients treated with eculizumab or ravulizumab across approved indications, with a specific focus on gMG and NMOSD. The data cutoff was October 1, 2025, for eculizumab and December 31, 2025, for ravulizumab. By 2025, across all approved indications, cumulative exposure to eculizumab and ravulizumab in the United States was 34,713 and 21,348 patient-years, respectively, and cumulative Nm infection and mortality rates remained relatively stable over time (eculizumab: 0.15 and 0.01 per 100 patient-years, respectively; ravulizumab: 0.08 and 0.01 per 100 patient-years, respectively). Cumulative Nm infection rates among eculizumab-treated patients with gMG and NMOSD were 0.05 and 0.12 per 100 patient-years, respectively. Cumulative Nm infection rates among ravulizumab-treated patients with gMG or NMOSD were 0.03 and 0.13 per 100 patient-years, respectively. No mortalities due to Nm were reported for eculizumab- or ravulizumab-treated patients with gMG or NMOSD. This real-world study demonstrates that Nm infection and associated mortality rates in the United States among patients receiving eculizumab or ravulizumab have remained stably low despite increasing patient-years of exposure to each treatment. These results suggest Nm-related risk mitigation strategies are effective in patients receiving eculizumab or ravulizumab.

1,063

项与依库珠单抗相关的新闻（医药）

2026-10-21

·国际糖尿病idiabetes

2篇入选高影响力临床试验专场！300余篇中国学者研究摘要亮相ASN 2026

编者按 2026年美国肾脏病学会肾脏周（ASN Kidney Week 2026）将于10月21—25日在美国丹佛举行。本届大会共收录中国学者（第一作者）研究摘要318篇，其中19篇入选最新突破摘要（Late-Breaking Abstracts，LBA）：1篇入选开幕式“高影响力临床试验精选”（Featured High-Impact Clinical Trials），1篇入选“高影响力临床试验”（High-Impact Clinical Trials）专场，17篇入选最新突破研究壁报（Late-Breaking Research Posters）。此外，23篇摘要入选口头报告专场（Oral Abstract Session）。从IgA肾病、膜性肾病的治疗探索，到透析相关并发症与血管通路管理，中国学者将在本届大会上分享多项研究成果。肾医线特梳理其中入选LBA的研究摘要，供读者提前关注。 Featured High-Impact Clinical Trials，1篇时间 10月22日，8:00~9:30 地点 Bluebird Ballroom 专题 Opening Plenary 9:19 AM TH-OR111 Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial – 第一作者：Jicheng Lv（吕继成） High-Impact Clinical Trials，1篇时间 10月23日，10:30~12:30 地点 Bluebird Ballroom 专题 Oral Abstract Session AM FR-OR102 HLX79 (E-602) Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy HLX79（E-602）联合利妥昔单抗使膜性肾病患者获得快速且持久的应答第一作者：Zhilian Li（李志莲）报告时间：10月23日11:00~11:15 Late-Breaking Research Posters，17篇时间 10月22日，10:00~12:00 地点 Exhibit Hall TH-PO1250 Telitacicept in Patients with Refractory IgA Nephropathy: A Randomized, Open-Label Clinical Trial 泰它西普治疗难治性IgA肾病：随机开放标签临床试验第一作者：Shang Liu TH-PO1251 Sarcopenic Obesity and Gut-Derived Glycylvaline in Relation to Myocardial Fibrosis in Patients with ESRD on Maintenance Dialysis 维持性透析终末期肾病患者肌少性肥胖、肠道来源甘氨酰缬氨酸与心肌纤维化的关系第一作者：Shang Liu TH-PO1255 A Randomized, Placebo-Controlled Phase 2 Trial of a Long-Acting, C3-Targeting siRNA in IgA Nephropathy 长效靶向C3的siRNA治疗IgA肾病：Ⅱ期随机安慰剂对照试验第一作者：Jicheng Lv吕继成 TH-PO1256 Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial 泰它西普治疗IgA肾病：Ⅲ期TELIGAN试验最终2年结果第一作者：Jicheng Lv（吕继成） TH-PO1259 Interim Phase 2 Results of SGB-9768, a Liver-Targeted GalNAc-siRNA-Targeting Complement C3, in IgA Nephropathy, C3 Glomerulopathy, and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) 肝脏靶向、靶向补体C3的GalNAc-siRNA SGB-9768治疗IgA肾病、C3肾小球病及原发性免疫复合物性膜增生性肾小球肾炎的Ⅱ期中期结果第一作者：Minghui Zhao（赵明辉） TH-PO1262 Efficacy and Safety of Eculizumab in Patients with Anti-Glomerular Basement Membrane Disease: An Investigator-Initiated, Open-Label, Phase 2 Clinical Trial 依库珠单抗治疗抗肾小球基底膜病的疗效与安全性：研究者发起的开放标签Ⅱ期临床试验第一作者：Huang Kuang TH-PO1264 Maintenance Rituximab Reduces Relapse in Phospholipase A2 Receptor (PLA2R)-Related Membranous Nephropathy: A Retrospective Cohort Study 利妥昔单抗维持治疗减少PLA2R相关膜性肾病复发：回顾性队列研究第一作者：Jingyuan Xie TH-PO1270 Biopsy-Guided Management Improves Renal Outcomes After Liver Transplantation: A Matched Cohort Study 肾活检指导的管理改善肝移植后肾脏结局：匹配队列研究第一作者：Xiaoyan Liu TH-PO1273 Niaoduqing Granules Improve Constipation in Patients with Peritoneal Dialysis: A Multicenter Prospective Controlled Study 尿毒清颗粒改善腹膜透析患者便秘：多中心前瞻性对照研究第一作者：Miao Li TH-PO1277 Efficacy and Safety of Gosicalcetide vs. Cinacalcet in Patients with Secondary Hyperparathyroidism Receiving Hemodialysis: Results from a Phase 3 Randomized Clinical Trial Gosicalcetide对比西那卡塞治疗血液透析继发性甲状旁腺功能亢进患者的疗效与安全性：Ⅲ期随机临床试验结果第一作者：Xueqing Yu（余学清） TH-PO1278 Long-Term Safety of Gosicalcetide in Patients with Secondary Hyperparathyroidism Receiving Hemodialysis Gosicalcetide在血液透析继发性甲状旁腺功能亢进患者中的长期安全性第一作者：Li Zuo（左力） TH-PO1279 Sodium Thiosulfate Attenuates Coronary Artery Calcification and Uremic Pruritus: A Randomized Crossover Trial 硫代硫酸钠减轻冠状动脉钙化及尿毒症瘙痒：随机交叉试验第一作者：Chensi Sun TH-PO1285 Proton Pump Inhibitor Use Is Associated with Improved Arteriovenous Fistula Patency in Patients with ESKD: A Retrospective Cohort Study with Experimental Support 质子泵抑制剂使用与终末期肾病患者动静脉内瘘通畅率改善相关：实验支持的回顾性队列研究第一作者：Yuchi Tu TH-PO1287 A Decellularized Biological Vascular Graft for Hemodialysis Access: 18-Month First-in-Human Clinical Outcomes of LineMatrix 去细胞生物血管移植物用于血液透析通路：LineMatrix首次人体应用18个月临床结局第一作者：Qiu Xuefeng TH-PO1288 Clinical Evaluation of a Novel Polyethersulfone Hemodiafiltration Filter: A Multicenter Randomized Crossover Noninferiority Trial 新型聚醚砜血液透析滤过器的临床评价：多中心随机交叉非劣效性试验 F第一作者：anna Liu（刘璠娜） TH-PO1296 First-in-Human Study of SK-09, a Novel Transient Receptor Potential iChannel-5 Inhibitor: Safety, Tolerability, and Pharmacokinetics in Healthy Participants 新型瞬时受体电位通道5抑制剂SK-09首次人体研究：健康受试者的安全性、耐受性及药代动力学第一作者：Du Ying（杜颖） TH-PO1298 Digital Cognitive Behavioral Therapy for Hyperkalemia in Patients on Maintenance Hemodialysis: A Prospective, Single-Center, Randomized Controlled Trial 数字化认知行为疗法治疗维持性血液透析患者高钾血症：前瞻性单中心随机对照试验第一作者：Hongli Lin（林洪丽） Oral Abstract Session，23篇声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《肾医线》编辑部）

siRNA临床2期临床结果

2026-10-21

·创药网

交易：Samsung Bioepis签署具有里程碑意义的10年协议，向巴西市场供应依库珠单抗，夯实拉丁美洲长期增长基础

2026年10月20日，Samsung Bioepis株式会社今日宣布，与其巴西本地合作伙伴——州级公共实验室Bahiafarma和本地制药领军企业Bionovis——达成一项具有里程碑意义的10年协议，向其依库珠单抗生物类似药SB12供应给巴西全民公共卫生系统（Sistema Único de Saúde，SUS）。该协议在巴西战略性产品开发伙伴关系（PDP）框架下形成，这一里程碑式协议扩大了Samsung Bioepis在拉丁美洲最大生物制药市场的布局。公司还通过与关键国内公共和私营合作伙伴组成联合体，深化了对该地区的承诺。“我们很自豪能够通过推进本地化生产合作伙伴关系，深化对巴西公共卫生事业的承诺，并为改善高质量药品的可及性做出贡献，”Samsung Bioepis国际市场营销战略副总裁兼负责人Jinhan Chung表示。“Samsung Bioepis与本地合作伙伴组成的联合体被选为依库珠单抗为期10年的独家供应商，这一长期协议不仅证明了我们的产品质量、卓越制造能力和供应可靠性，也是我们在拉丁美洲持续增长的基石。此外，通过将合作伙伴多元化至州级合作方，我们正在扩大对巴西各地区生物制药产业均衡发展的贡献。我们期待与本地合作伙伴携手，为巴西生物制药产业的长期发展做出贡献。”PDP模式是巴西国家卫生战略的关键驱动力之一，旨在增强SUS的可持续性。PDP计划由巴西政府于2008年推出，通过促进成熟企业的技术转让以换取SUS的保证采购，支持该国制药产业的发展。巴西卫生部（MoH）一直在扩大PDP计划以纳入罕见病，从而增加本地生产并扩大罕见病患者——他们往往面临有限治疗选择和昂贵护理——的可及性。在巴西，所有公民和居民均有资格享受SUS，80%的人口完全依赖SUS获得医疗保健覆盖。¹ 虽然生物制品约占SUS采购的所有药品的12%，但其约占政府药品采购支出的60%。²SB12的纳入直接应对了重大的预算和公共卫生挑战。依库珠单抗是卫生部支出最高的单一专科药物，仅2025年年度公共支出就超过9.47亿巴西雷亚尔（约合1.71亿美元）。³ 通过提供临床等效、成本效益高的生物类似药，这一10年期PDP使卫生部能够缓解严重的预算压力，并探索扩大此前面临治疗障碍患者的可及性。目前，参比依库珠单抗在SUS中仅覆盖其获批适应症之一：阵发性睡眠性血红蛋白尿症（PNH）。根据PDP，Samsung Bioepis将向本地合作伙伴供应成品，以便自2027年起在10年期间向SUS销售。在此期间，Samsung Bioepis将提供技术转让，使生产责任能够逐步转移至本地合作伙伴，从而实现在巴西的本地化生产。SB12是Samsung Bioepis的依库珠单抗，于2024年12月被巴西卫生监管局（Agência Nacional de Vigilância Sanitária，ANVISA）批准为Soliris⁴的生物类似药。其适应症为治疗患有PNH和非典型溶血性尿毒症综合征（aHUS）的成人和儿童患者。关于Samsung Bioepis株式会社Samsung Bioepis成立于2012年，是一家致力于实现人人可及医疗保健的生物制药公司。通过产品开发创新和对质量的坚定承诺，Samsung Bioepis力求成为世界领先的生物制药公司。作为Samsung Epis Holdings（KRX: 0126Z0）的全资子公司，Samsung Bioepis持续推进广泛的生物制品候选药物管线，覆盖免疫学、肿瘤学、眼科学、血液学、肾脏病学、内分泌学和神经学等多个治疗领域。i The Commonwealth Fund. International Health Care System Profiles: Brazil. Available at: https://www.commonwealthfund.org/international-health-policy-center/countries/brazil (Accessed October 2026)ii Pontes MA, Ribeiro AA, Albuquerque FC, Leite Cotenzini SN. Comparative price analysis of biological medicines: disparities generated by different pricing policies. Front Pharmacol. 2024 Jan 11;14:1256542. doi: 10.3389/fphar.2023.1256542. PMID: 38273835; PMCID: PMC10808539.iii IQVIA Non-Retail Brazil HPP database 2025. USD based on exchange rate as of December 31, 2025.iv Soliris is a trademark of Alexion Pharmaceuticals, Inc.

生物类似药带量采购

2026-10-21

·Pharma Manufacturing

Samsung Bioepis signs 10-year eculizumab supply deal in Brazil

Samsung Bioepis, a South Korea-based biopharmaceutical company, has been selected with Brazilian partners Bahiafarma and Bionovis as the sole supplier of its eculizumab biosimilar (SB12) to Brazil’s public health system under a 10-year agreement beginning in 2027. The agreement falls under Brazil’s Productive Development Partnership (PDP) framework, which supports technology transfer and domestic pharmaceutical manufacturing in exchange for government purchases. Samsung Bioepis will initially supply finished product to its local partners, with manufacturing responsibilities gradually transferring to the partners over the agreement’s 10-year term, according to the announcement . The partnership is intended to expand access to eculizumab through Brazil’s Sistema Único de Saúde (SUS), the country’s universal public health system. In 2025, public spending on eculizumab exceeded 947 million Brazilian reals, or approximately $171 million, according to IQVIA data cited by Samsung Bioepis. Brazil’s health system currently covers the reference eculizumab product for paroxysmal nocturnal hemoglobinuria (PNH), one of the drug’s approved indications. SB12 is approved in Brazil for treating adults and children with PNH and atypical hemolytic uremic syndrome (aHUS), according to the company. Brazil’s Health Regulatory Agency approved SB12 as a biosimilar in December 2024. Under the new agreement, technology transfer is expected to enable local manufacturing as production responsibilities shift to Bahiafarma and Bionovis. Samsung Bioepis said the agreement builds on its previous PDP partnerships to supply etanercept and trastuzumab to Brazil’s public health system.

上市批准

100 项与依库珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03940	依库珠单抗	L04AJ01	DB01257

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
水通道蛋白4抗体阳性视神经脊髓炎谱系疾病	澳大利亚	Alexion Pharmaceuticals, Inc.	2009-03-20
非典型溶血性尿毒症综合征	欧盟	Alexion Europe SAS	2007-06-20
非典型溶血性尿毒症综合征	冰岛	Alexion Europe SAS	2007-06-20
非典型溶血性尿毒症综合征	列支敦士登	Alexion Europe SAS	2007-06-20
非典型溶血性尿毒症综合征	挪威	Alexion Europe SAS	2007-06-20
重症肌无力	欧盟	Alexion Europe SAS	2007-06-20
重症肌无力	冰岛	Alexion Europe SAS	2007-06-20
重症肌无力	列支敦士登	Alexion Europe SAS	2007-06-20
重症肌无力	挪威	Alexion Europe SAS	2007-06-20
视神经脊髓炎	欧盟	Alexion Europe SAS	2007-06-20
视神经脊髓炎	冰岛	Alexion Europe SAS	2007-06-20
视神经脊髓炎	列支敦士登	Alexion Europe SAS	2007-06-20
视神经脊髓炎	挪威	Alexion Europe SAS	2007-06-20
阵发性睡眠性血红蛋白尿症	美国	Alexion Pharmaceuticals, Inc.	2007-03-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
移植物功能延迟恢复	临床3期	美国	Alexion Pharmaceuticals, Inc.	2014-08-21
移植物功能延迟恢复	临床3期	澳大利亚	Alexion Pharmaceuticals, Inc.	2014-08-21
移植物功能延迟恢复	临床3期	巴西	Alexion Pharmaceuticals, Inc.	2014-08-21
移植物功能延迟恢复	临床3期	加拿大	Alexion Pharmaceuticals, Inc.	2014-08-21
移植物功能延迟恢复	临床3期	捷克	Alexion Pharmaceuticals, Inc.	2014-08-21
移植物功能延迟恢复	临床3期	法国	Alexion Pharmaceuticals, Inc.	2014-08-21
移植物功能延迟恢复	临床3期	德国	Alexion Pharmaceuticals, Inc.	2014-08-21
移植物功能延迟恢复	临床3期	意大利	Alexion Pharmaceuticals, Inc.	2014-08-21
移植物功能延迟恢复	临床3期	西班牙	Alexion Pharmaceuticals, Inc.	2014-08-21
水通道蛋白4抗体阳性视神经炎	临床3期	美国	Alexion Pharmaceuticals, Inc.	2014-04-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2026	N/A	抗磷脂综合征	7	Eculizumab	選廠網遞製築膚簾繭廠(獵糧觸願遞廠蓋願襯艱) = One patient developed non-disseminated herpes zoster reactivation 鹹淵築網觸餘廠憲製鏇 (獵鏇範繭淵築鹽糧鬱鏇 )	积极	2026-11-06
NCT02145182 (Pubmed \| Am J Transplant)	临床2/3期	移植物功能延迟恢复	288	Eculizumab	鹹廠膚積鹽網構窪觸蓋(網醖簾夢齋繭膚廠觸鏇) = 鏇鑰願憲齋鏇淵構範築醖淵衊範膚積衊簾齋糧 (繭醖獵選餘糧築築窪憲 )	不佳	2026-09-01
				Placebo	鹹廠膚積鹽網構窪觸蓋(網醖簾夢齋繭膚廠觸鏇) = 遞衊衊蓋壓餘網膚壓夢醖淵衊範膚積衊簾齋糧 (繭醖獵選餘糧築築窪憲 )
EULAR2026	N/A	抗磷脂综合征	100	Rituximab	窪糧鹽範獵遞鬱積積餘(壓構遞廠鹽餘構顧構製) = 襯膚積醖醖膚淵網餘鏇製糧範膚鏇蓋構窪積艱 (繭積鹹簾襯鬱襯壓醖糧 ) 更多	积极	2026-06-11
				Eculizumab	構衊膚艱遞憲願構餘鏇(窪膚鬱鑰遞網範鬱淵鏇) = 艱願壓鏇範淵網鏇淵壓製淵鏇艱淵鬱選齋遞艱 (遞繭觸艱繭網衊淵餘選 )
EHA2026	N/A	镰状细胞血症	5	Eculizumab	膚遞壓顧網鑰積鹹襯艱(衊顧襯鏇廠窪蓋製鹹醖) = 簾獵網憲衊網顧構衊簾網醖築獵廠遞範壓醖窪 (構夢鏇餘鹽構繭襯蓋積 )	积极	2026-05-12
EHA2026	N/A	阵发性睡眠性血红蛋白尿症	10	EculizumabDanicopanRavulizumabPegcetacoplan + EculizumabDanicopanRavulizumabPegcetacoplan + EculizumabDanicopanRavulizumabPegcetacoplan + EculizumabDanicopanRavulizumabPegcetacoplan	簾餘艱醖窪鏇選積遞憲(鹽壓築製壓築廠獵淵壓) = During a median follow-up of 49.5 months, 3/10 patients required therapy modification due to persistent anemia compatible with EVH. 齋餘壓淵選艱衊餘獵構 (淵築範膚齋築蓋製餘鏇 )	积极	2026-05-12
EHA2026	N/A	阵发性睡眠性血红蛋白尿症	38	Eculizumab	願鹽範鏇遞膚繭簾鬱衊(襯積壓艱鹹網觸餘範製) = 廠構鬱製夢願構膚構構選積網鏇獵網鹹醖膚鹽 (鏇膚選網衊餘簾積蓋鹽 ) 更多	积极	2026-05-12
				Iptacopan	願鹽範鏇遞膚繭簾鬱衊(襯積壓艱鹹網觸餘範製) = 壓窪襯餘網廠窪淵繭憲選積網鏇獵網鹹醖膚鹽 (鏇膚選網衊餘簾積蓋鹽 ) 更多
AAN2026	N/A	视神经脊髓炎	225	Eculizumab	願窪壓積鹽窪淵獵膚醖(壓糧獵構鬱製網衊壓壓) = 鏇蓋鬱鏇簾顧鏇膚顧蓋襯觸築觸膚糧簾襯製糧 (憲網餘選艱淵獵顧鹹襯 )	积极	2026-04-25
				Placebo	餘選製蓋願齋繭糧選構(蓋繭網繭構醖艱顧遞鏇) = 襯繭鹹繭選選積膚糧鹽築蓋網顧範鹹鬱齋觸餘 (衊範獵夢齋淵繭簾壓築 )
NCT05966467 (NMO SPOTLIGHT Registry, AAN2026)	N/A	视神经脊髓炎 AQP4-Ab+	56	Eculizumab and Ravulizumab	襯構簾鏇鏇廠壓醖積鹽(遞範簾積製築築艱鹹餘) = 膚獵淵艱齋鬱窪鏇範簾顧淵選鹹築壓選夢願獵 (鬱廠糧築鑰餘遞願顧積, 0.33 ~ 0.72) 更多	积极	2026-04-25
				Eculizumab and Ravulizumab (Switched from RTX)	襯構簾鏇鏇廠壓醖積鹽(遞範簾積製築築艱鹹餘) = 構蓋鏇築積繭壓鑰鑰鬱顧淵選鹹築壓選夢願獵 (鬱廠糧築鑰餘遞願顧積, 0.19 ~ 0.96) 更多
AAN2026	N/A	重症肌无力	23	Novel Therapy Group (N)	憲淵憲網製廠網積願艱(壓遞繭鬱淵繭窪餘網製) = 構築選觸衊觸鬱築壓願襯醖範願憲淵膚築繭醖 (鏇鑰繭觸壓鬱範鹹願鬱 )	积极	2026-04-25
				Traditional Therapy Group (T)	憲淵憲網製廠網積願艱(壓遞繭鬱淵繭窪餘網製) = 積繭製鏇淵憲繭積製構襯醖範願憲淵膚築繭醖 (鏇鑰繭觸壓鬱範鹹願鬱 )
ISN WCN2026	N/A	免疫球蛋白a肾病	8	Eculizumab	遞構壓選簾築憲膚範襯(鹹築鬱襯獵積鹹築繭膚) = mild (nasopharyngitis, headache) and resolved with symptomatic management; no severe AEs occurred 鑰築獵艱鹽壓願齋繭鬱 (構餘蓋膚衊憲糧網鹽鬱 )	积极	2026-04-01